PMID- 24969008
OWN - NLM
STAT- MEDLINE
DCOM- 20140825
LR  - 20220410
IS  - 1524-4733 (Electronic)
IS  - 1098-3015 (Linking)
VI  - 17
IP  - 4
DP  - 2014 Jun
TI  - Review of utility values for economic modeling in type 2 diabetes.
PG  - 462-70
LID - S1098-3015(14)00054-0 [pii]
LID - 10.1016/j.jval.2014.03.003 [doi]
AB  - OBJECTIVES: Economic analysis in type 2 diabetes mellitus (T2DM) requires an 
      assessment of the effect of a wide range of complications. The objective of this 
      article was to identify a set of utility values consistent with the National 
      Institute for Health and Care Excellence (NICE) reference case and to critically 
      discuss and illustrate challenges in creating such a utility set. METHODS: A 
      systematic literature review was conducted to identify studies reporting utility 
      values for relevant complications. The methodology of each study was assessed for 
      consistency with the NICE reference case. A suggested set of utility values 
      applicable to modeling was derived, giving preference to studies reporting 
      multiple complications and correcting for comorbidity. RESULTS: The review 
      considered 21 relevant diabetes complications. A total of 16,574 articles were 
      identified; after screening, 61 articles were assessed for methodological 
      quality. Nineteen articles met NICE criteria, reporting utility values for 20 of 
      21 relevant complications. For renal transplant, because no articles meeting NICE 
      criteria were identified, two articles using other methodologies were included. 
      Index value estimates for T2DM without complication ranged from 0.711 to 0.940. 
      Utility decrement associated with complications ranged from 0.014 (minor 
      hypoglycemia) to 0.28 (amputation). Limitations associated with the selection of 
      a utility value for use in economic modeling included variability in patient 
      recruitment, heterogeneity in statistical analysis, large variability around some 
      point estimates, and lack of recent data. CONCLUSIONS: A reference set of utility 
      values for T2DM and its complications in line with NICE requirements was 
      identified. This research illustrates the challenges associated with 
      systematically selecting utility data for economic evaluations.
CI  - Copyright (c) 2014 International Society for Pharmacoeconomics and Outcomes 
      Research (ISPOR). Published by Elsevier Inc. All rights reserved.
FAU - Beaudet, Amelie
AU  - Beaudet A
AD  - IMS Health, Basel, Switzerland. Electronic address: abeaudet@ch.imshealth.com.
FAU - Clegg, John
AU  - Clegg J
AD  - IMS Health, Basel, Switzerland.
FAU - Thuresson, Per-Olof
AU  - Thuresson PO
AD  - IMS Health, Basel, Switzerland.
FAU - Lloyd, Adam
AU  - Lloyd A
AD  - IMS Health, London, UK.
FAU - McEwan, Phil
AU  - McEwan P
AD  - Centre for Health Economics, Swansea University, Swansea, UK.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PT  - Systematic Review
DEP - 20140517
PL  - United States
TA  - Value Health
JT  - Value in health : the journal of the International Society for Pharmacoeconomics 
      and Outcomes Research
JID - 100883818
SB  - IM
MH  - Cost-Benefit Analysis
MH  - Diabetes Complications/*economics
MH  - Diabetes Mellitus, Type 2/*economics
MH  - Health Status
MH  - Humans
MH  - *Models, Economic
MH  - *Quality of Life
OTO - NOTNLM
OT  - EQ-5D
OT  - diabetes
OT  - quality of life
OT  - systematic review
OT  - utility
EDAT- 2014/06/28 06:00
MHDA- 2014/08/26 06:00
CRDT- 2014/06/28 06:00
PHST- 2013/03/15 00:00 [received]
PHST- 2014/03/05 00:00 [revised]
PHST- 2014/03/11 00:00 [accepted]
PHST- 2014/06/28 06:00 [entrez]
PHST- 2014/06/28 06:00 [pubmed]
PHST- 2014/08/26 06:00 [medline]
AID - S1098-3015(14)00054-0 [pii]
AID - 10.1016/j.jval.2014.03.003 [doi]
PST - ppublish
SO  - Value Health. 2014 Jun;17(4):462-70. doi: 10.1016/j.jval.2014.03.003. Epub 2014 
      May 17.